Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 2101 to 2110 of 2586 total matches.
Melatonin for Insomnia in Children
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020 (Issue 1601)
of insomnia in normal children and those
with neurodevelopmental disorders such as ASD and
ADHD.4,5 No drugs ...
Over-the-counter products containing melatonin are
widely used as sleep aids in children and adults.
Tirbanibulin 1% Ointment (Klisyri) for Actinic Keratosis
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
ingenol mebutate gel (Picato) has been discontinued
Table 1. Some Topical Drugs for Actinic Keratosis ...
Tirbanibulin, a microtubule inhibitor, has been
approved by the FDA as a 1% ointment (Klisyri –
Almirall) for topical treatment of actinic keratosis of
the face or scalp.
Cefepime/Enmetazobactam (Exblifep) for Complicated Urinary Tract Infections
The Medical Letter on Drugs and Therapeutics • Jul 22, 2024 (Issue 1707)
milk; the drug is present in the milk of lactating rats.9
DOSAGE AND ADMINISTRATION — The recommended ...
The FDA has approved Exblifep (Allecra), a fixed-dose
combination of the cephalosporin cefepime and the
beta-lactamase inhibitor enmetazobactam, for IV
treatment of adults with complicated urinary tract
infections (cUTIs), including pyelonephritis, caused
by designated susceptible microorganisms (see
Spectrum of Activity). Exblifep is the first product that
contains enmetazobactam to be approved in the US.
Med Lett Drugs Ther. 2024 Jul 22;66(1707):117-8 doi:10.58347/tml.2024.1707d | Show Introduction Hide Introduction
Treatment of Heat Injury
The Medical Letter on Drugs and Therapeutics • Jul 13, 1990 (Issue 822)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Summer heat waves cause thousands of cases of heat-related illness in the USA each year and hundreds of heat-related deaths, especially among the elderly. A few principles may be helpful in preventing and treating heat injury.
Nisoldipine-A New Calcium-Channel Blocker for Hypertension
The Medical Letter on Drugs and Therapeutics • Feb 16, 1996 (Issue 968)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Nisoldipine (Sular -Zeneca), a dihydropyridine calcium-channel blocker structurally similar to nifedipine, has been approved for marketing by the US Food and Drug Administration. It is available in an oral extended-release formulation for treatment of hypertension.
Update on Glucosamine For Osteoarthritis
The Medical Letter on Drugs and Therapeutics • Dec 10, 2001 (Issue 1120)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Since the last Medical Letter article on glucosamine for osteoarthritis (vol.39, page 91, September 26, 1997), more data have become available. Glucosamine is available in US pharmacies and health food stores as sulfate, hydrochloride or n-acetyl salt.
Anastrozole (Arimidex) vs. Tamoxifen for Treatment of Early Breast Cancer
The Medical Letter on Drugs and Therapeutics • Mar 17, 2003 (Issue 1152)
The Medical Letter
On Drugs and Therapeutics
www.medicalletter.org
Published by The Medical ...
Anastrozole (Arimidex - AstraZeneca, Medical Letter 1996; 38:61), an aromatase inhibitor, has received accelerated approval from the FDA for adjuvant treatment of postmenopausal women with early hormone-receptor-positive breast cancer. The drug was approved for treatment of postmenopausal women with metastatic breast cancer in 1996.
Olanzapine/Fluoxetine (Symbyax) for Bipolar Depression
The Medical Letter on Drugs and Therapeutics • Mar 15, 2004 (Issue 1178)
®
On Drugs and Therapeutics
www.medicalletter.org
Published by The Medical Letter, Inc. 1000 Main Street ...
The fixed-dose combination of olanzapine and fluoxetine (Symbyax - Lilly) has been approved by the FDA for treatment of depressive episodes associated with bipolar disorder. Olanzapine alone (Zyprexa), which is mainly used as an antipsychotic (Medical Letter 2003; 45:102), is FDA-approved for treatment of acute manic episodes and for maintenance treatment of bipolar disorder. Fluoxetine alone (Prozac, and others), which is mainly used as an antidepressant (Medical Letter 2003; 45:93), has no specific approval for use in bipolar...
Botulinum Toxin (Botox) for Axillary Hyperhidrosis
The Medical Letter on Drugs and Therapeutics • Sep 13, 2004 (Issue 1191)
Volume 46 (Issue 1191)
September 13, 2004
www.medicalletter.org
The Medical Letter
®
On Drugs ...
Botulinum toxin type A (Botox - Allergan) has been approved by the FDA for treatment of severe underarm sweating ("primary axillary hyperhidrosis"). Injected into the skin, botulinum toxin decreases sweating by causing chemical denervation of the sweat gland.
Tretinoin/Benzoyl Peroxide Cream (Twyneo) for Acne
The Medical Letter on Drugs and Therapeutics • May 16, 2022 (Issue 1650)
Drug Formulations1 Cost/Size2
Adapalene/benzoyl peroxide –
Epiduo (Galderma) 0.1%/2.5% gel $412.00/45 ...
The FDA has approved Twyneo (Galderma), a cream
containing the retinoid tretinoin and the oxidizing
agent benzoyl peroxide, for once-daily topical
treatment of acne in patients ≥9 years old.